112P - Macrophage inhibitory cytokine-1 as a biomarker for diagnosis and prognosis of stage I–II non-small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Non-small-cell lung cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Yu-Ning Liu
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors Y. Liu, D. Shen, K. Sun
  • Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN

Abstract

Background

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death and has a poor prognosis. Biomarkers should be established to improve patient care especially in early-stage NSCLC. The macrophage inhibitory cytokine-1 (MIC-1) can promote tumor invasiveness and metastasis. Therefore, our aim was to delineate the diagnostic and prognostic value of serum MIC-1 in patients with early-stage NSCLC.

Methods

A total of 152 consecutive patients with stage I–II NSCLC were retrospectively reviewed and underwent follow up after total resection of tumor. Serum MIC-1 level was evaluated in patients and 229 healthy controls, and was correlated with clinical features and prognosis of patients.

Results

The level of MIC-1 of NSCLC patients was significantly higher than that of controls (P 60 years old) at diagnosis (P = 0.001) and female gender (P = 0.03). There was a significant difference between the overall survival for patients with high level of MIC-1 (≥1000 pg/ml) and low level of MIC-1(log rank, P = 0.045). The overall 3-year survival rate in patients with high level of MIC-1 was significantly lower than that of patients with low MIC-1 level (84.0% vs. 97.8%, P 

Conclusions

The high level of serum MIC-1 might be served as a potential biomarker for diagnosis and poorer outcome in patients with early-stage NSCLC. The clinical significance could be evaluated in future studies with larger sample size.

Clinical trial identification

Legal entity responsible for the study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Funding

Beijing Marathon of Hope special fund clinical topics

Disclosure

All authors have declared no conflicts of interest.